Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
Deception at the Cannes Lions Festival
Misleading campaigns highlight this year’s big ad event.
True Tone’s ‘Tan-Through’ Swimwear
Consumers may want to see through many of this company’s claims.
Court Cancels ‘Click-to-Cancel’ Rule
It won’t get any easier to cancel those annoying subscriptions.
Ribena – There’s No Taste Like Home
This soft drink reminds consumers of the good old days.
US Cellular: ‘Four Free Phones and Four Lines for $90’
What you need to know about this offer.